Desirudin

Drug Profile

Desirudin

Alternative Names: CGP 39393; Desulfatohirudin recombinant; Iprivask; r-Hirudin; Revasc

Latest Information Update: 24 Mar 2015

Price : $50

At a glance

  • Originator Novartis
  • Developer Canyon Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Hirudins; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis
  • Clinical Phase Unknown Thrombosis

Most Recent Events

  • 23 Feb 2015 Valeant Pharmaceuticals acquires desirudin from Marathon Pharmaceuticals
  • 05 Dec 2013 Marathon Pharmaceuticals acquires desirudin from Canyon Pharmaceuticals
  • 16 Apr 2010 Interim efficacy and adverse event data from a phase II trial in thrombosis prophylaxis released by Canyon Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top